cytomx therapeutics inc - CTMX
CTMX
Close Chg Chg %
4.40 -0.01 -0.23%
Closed Market
4.39
-0.01 (0.23%)
Volume: 1.39M
Last Updated:
Dec 26, 2025, 4:00 PM EDT
Company Overview: cytomx therapeutics inc - CTMX
CTMX Key Data
| Open $4.43 | Day Range 4.27 - 4.48 |
| 52 Week Range 0.40 - 4.62 | Market Cap $745.51M |
| Shares Outstanding 169.44M | Public Float 127.86M |
| Beta 2.37 | Rev. Per Employee N/A |
| P/E Ratio 10.52 | EPS $0.42 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.84M |
CTMX Performance
| 1 Week | 9.75% | ||
| 1 Month | 2.57% | ||
| 3 Months | 51.38% | ||
| 1 Year | 310.28% | ||
| 5 Years | -40.84% |
CTMX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About cytomx therapeutics inc - CTMX
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
CTMX At a Glance
CytomX Therapeutics, Inc.
151 Oyster Point Boulevard
South San Francisco, California 94080-1913
| Phone | 1-605-515-3185 | Revenue | 138.10M | |
| Industry | Pharmaceuticals: Major | Net Income | 31.87M | |
| Sector | Health Technology | 2024 Sales Growth | 36.447% | |
| Fiscal Year-end | 12 / 2025 | Employees | 121 | |
| View SEC Filings |
CTMX Valuation
| P/E Current | 10.521 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 2.739 |
| Price to Sales Ratio | 0.632 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.148 |
| Enterprise Value to Sales | -0.029 |
| Total Debt to Enterprise Value | -2.376 |
CTMX Efficiency
| Revenue/Employee | 1,141,347.107 |
| Income Per Employee | 263,380.165 |
| Receivables Turnover | 44.506 |
| Total Asset Turnover | 0.843 |
CTMX Liquidity
| Current Ratio | 1.251 |
| Quick Ratio | 1.251 |
| Cash Ratio | 1.173 |
CTMX Profitability
| Gross Margin | 98.72 |
| Operating Margin | 18.099 |
| Pretax Margin | 23.238 |
| Net Margin | 23.076 |
| Return on Assets | 19.445 |
| Return on Equity | N/A |
| Return on Total Capital | 356.916 |
| Return on Invested Capital | N/A |
CTMX Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 105.107 |
| Total Debt to Total Assets | 7.652 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 47.486 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Cytomx Therapeutics Inc - CTMX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 69.57M | 53.16M | 101.21M | 138.10M | |
Sales Growth
| -30.68% | -23.59% | +90.38% | +36.45% | |
Cost of Goods Sold (COGS) incl D&A
| 5.84M | 5.86M | 2.17M | 1.77M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 5.84M | 5.86M | 2.17M | 1.77M | |
Depreciation
| 5.69M | 5.71M | 2.03M | 1.62M | |
Amortization of Intangibles
| 146.00K | 146.00K | 146.00K | 146.00K | |
COGS Growth
| - | +0.29% | -62.86% | -18.71% | |
Gross Income
| 63.73M | 47.31M | 99.04M | 136.34M | |
Gross Income Growth
| - | -25.77% | +109.35% | +37.66% | |
Gross Profit Margin
| +91.61% | +88.98% | +97.85% | +98.72% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 147.51M | 140.94M | 105.52M | 111.34M | |
Research & Development
| 111.63M | 104.05M | 75.65M | 81.76M | |
Other SG&A
| 35.88M | 36.89M | 29.87M | 29.58M | |
SGA Growth
| +2.79% | -4.46% | -25.13% | +5.51% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 7.70M | - |
EBIT after Unusual Expense
| (83.78M) | (101.34M) | (6.48M) | 25.00M | |
Non Operating Income/Expense
| 172.00K | 2.02M | 9.81M | 7.10M | |
Non-Operating Interest Income
| 255.00K | 1.68M | 9.84M | 7.14M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (83.61M) | (99.32M) | 3.32M | 32.09M | |
Pretax Income Growth
| -78.67% | -18.79% | +103.35% | +865.78% | |
Pretax Margin
| -120.17% | -186.82% | +3.28% | +23.24% | |
Income Tax
| - | - | 3.89M | 224.00K | - |
Income Tax - Current - Domestic
| - | - | 3.89M | 224.00K | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (83.61M) | (99.32M) | (569.00K) | 31.87M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (83.61M) | (99.32M) | (569.00K) | 31.87M | |
Net Income Growth
| -154.25% | -18.79% | +99.43% | +5,700.88% | |
Net Margin Growth
| -120.17% | -186.82% | -0.56% | +23.08% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (83.61M) | (99.32M) | (569.00K) | 31.87M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (83.61M) | (99.32M) | (569.00K) | 31.87M | |
EPS (Basic)
| -1.3034 | -1.5108 | -0.0077 | 0.3774 | |
EPS (Basic) Growth
| -82.91% | -15.91% | +99.49% | +5,001.30% | |
Basic Shares Outstanding
| 64.15M | 65.74M | 73.81M | 84.44M | |
EPS (Diluted)
| -1.3034 | -1.5108 | -0.0077 | 0.3761 | |
EPS (Diluted) Growth
| -82.91% | -15.91% | +99.49% | +4,984.42% | |
Diluted Shares Outstanding
| 64.15M | 65.74M | 73.81M | 84.75M | |
EBITDA
| (77.94M) | (87.78M) | (4.31M) | 26.76M | |
EBITDA Growth
| -80.65% | -12.62% | +95.09% | +721.10% | |
EBITDA Margin
| -112.03% | -165.11% | -4.26% | +19.38% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 6.357 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.094 | |
| FY Report Date | 12 / 2025 | Current Year's Estimate | -0.034 | |
| Last Quarter’s Earnings | -0.09 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.38 | Next Fiscal Year Estimate | -0.382 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 8 | 5 | 8 | 8 |
| Mean Estimate | -0.09 | -0.10 | -0.03 | -0.38 |
| High Estimates | -0.03 | -0.08 | 0.02 | -0.21 |
| Low Estimate | -0.17 | -0.11 | -0.06 | -0.54 |
| Coefficient of Variance | -40.20 | -12.48 | -76.56 | -31.46 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 6 | 6 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Cytomx Therapeutics Inc - CTMX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Cytomx Therapeutics Inc - CTMX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Sean A. McCarthy CEO; Director | 995,195 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.6 per share | 597,117.00 |
| Mar 21, 2025 | Lloyd A. Rowland General Counsel | 120,594 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.6 per share | 72,356.40 |
| Mar 21, 2025 | Yu Waye Chu Chief Medical Officer | 135,725 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.6 per share | 81,435.00 |
| Mar 21, 2025 | Chris Ogden Chief Financial Officer | 201,026 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.6 per share | 120,615.60 |
| Mar 21, 2025 | Marcia P. Belvin SVP, Chief Scientific Officer | 248,636 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $0.6 per share | 149,181.60 |
| Feb 7, 2025 | Chris Ogden Chief Financial Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Chris Ogden Chief Financial Officer | 225,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Chris Ogden Chief Financial Officer | 209,577 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Marcia P. Belvin SVP, Chief Scientific Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Marcia P. Belvin SVP, Chief Scientific Officer | 140,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Marcia P. Belvin SVP, Chief Scientific Officer | 263,148 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Yu Waye Chu Chief Medical Officer | 115,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Yu Waye Chu Chief Medical Officer | 238,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Yu Waye Chu Chief Medical Officer | 139,750 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Sean A. McCarthy CEO; Director | 390,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Sean A. McCarthy CEO; Director | 800,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Feb 7, 2025 | Sean A. McCarthy CEO; Director | 1,032,851 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |